# Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis

> **NCT02869802** · — · RECRUITING · sponsor: **British Columbia Cancer Agency** · enrollment: 190 (estimated)

## Conditions studied

- Cancer
- Pancreatic Cancer

## Interventions

- **PROCEDURE:** Tumour Biopsy
- **OTHER:** Serial Collection of Plasma and Serum Samples

## Key facts

- **NCT ID:** NCT02869802
- **Lead sponsor:** British Columbia Cancer Agency
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2016-10-06
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2025-09-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02869802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02869802, "Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02869802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*